A 5% Reduction in Brain Cell Injury Volume Significant for Argenica's Acute Ischemic Stroke Treatment Candidate, Euroz Hartleys Says
MT Newswires Live
Jul 23
A 5% to 10% reduction in the volume of brain cell injury would be considered clinically and commercially meaningful for Argenica Therapeutics' (ASX:AGN) lead treatment candidate, ARG-007, which is being developed as a neuroprotective therapy for acute ischemic stroke, Euroz Hartleys said in a note on Wednesday.
It is currently in a phase two trial in acute ischemic stroke patients with large vessel occlusion who have undergone endovascular thrombectomy. Top-line results are expected in the third quarter.
The firm added that the literature suggests that even a 1.6% reduction could be considered clinically meaningful.
Euroz Hartleys has a speculative buy rating for the firm with a price target of AU$1.40.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.